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Background: Never-smokers comprise up to 25% of all lung cancer 
cases. They could have different molecular pathways for lung cancer 
induction compared with smokers. Alpha-1 antitrypsin (AAT) defi-
ciency is a hereditary trait whose main characteristic is early onset 
of lung emphysema. Our aim is to know if AAT-deficient carriers 
have a higher risk of lung cancer in a study performed exclusively in 
never-smokers.
Methods: We designed a multicentre hospital-based case–control 
study, which included incident never-smoking lung cancer cases. 
Controls were never-smokers attending nonmajor surgery at the par-
ticipating hospitals. Controls were frequency matched on age and 
gender with cases. We determined AAT variants (alleles S and Z) 
through polymerase chain reaction.
Results: Two hundred and twelve cases and 318 controls were 
included. PiSS individuals showed a lung cancer risk of 4.64 
(95% confidence interval: 1.08–19.92) compared with those with 
normal genotype (PiMM). When the analysis was restricted to 
women, the risk for PiSS increased to 7.58 (95% confidence inter-
val: 1.40–40.87). This risk for homozygous SS was even higher for 
individuals exposed to environmental tobacco smoke (greater than 
20 years). The presence of other alleles did not show any effect on 
lung cancer risk.
Conclusions: Never smoking SS homozygous individuals pose 
an increased risk of lung cancer. The risk is higher for individuals 
exposed to environmental tobacco smoke.
Key Words: Lung cancer, Alpha-1 antitrypsin deficiency, Never-
smokers, Environmental tobacco smoke, Residential radon.
(J Thorac Oncol. 2015;10: 1279–1284)
Lung cancer is a worldwide health problem. It is currently the leading cause of cancer death.1 Although the main 
risk factor is tobacco consumption, up to 25% of all cases 
are diagnosed in never-smokers, with important geographic 
variations.2 The most important risk factor in never-smokers 
is residential radon.3,4 Lung cancer in never-smokers has 
been proposed as a different disease than lung cancer occur-
ring in ever-smokers due to different molecular pathways.5,6 
Nevertheless, the available studies are still scarce.
Alpha-1 antitrypsin deficiency (AATD) is a hereditary 
condition first described by Laurell and Eriksson.7 Alpha-1 
antitrypsin (AAT) is a glycoprotein codified by SERPINE1 
gen, placed in the long arm of chromosome 14. It is synthesized 
mainly in the liver and its main function is to inhibit neutrophil 
elasthase and other serine proteases. It provides more than 90% 
of the total antiprotease capacity of the organism8 and, in the 
past years, it has been described that it has anti-inflammatory9 
and inmunomodulatory10 properties, among others.
AAT gene comprises two alleles that are transmitted 
through a codominant autosomic Mendelian pattern. Wild 
alleles are named M and are present in 85%–90% of individ-
uals (MM). The most frequent deficient alleles are called S 
and Z and are present in 10% and 2% of Spanish population, 
respectively,11 although there are very few published studies. 
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The severity of the deficiency is related to the deficient allele. 
The S allele expresses around 40% of AAT and the Z allele 
expresses around 15%.
The main AATD clinical symptom is the early develop-
ment of lung emphysema, mainly in individuals exposed to 
tobacco smoke. It is also known its association with bronchi-
ectasis, panniculitis, and ANCA+ vasculitis. Some investiga-
tions have been published in the past years associating AATD 
with fibromyalgia or asthma.12–14
The imbalance protease–antiprotease originated from 
the low AAT concentration in blood and tissues causes a lower 
protection against proteases, being the most important neutro-
phil elastase, and is the cause of the harm that finally produces 
lung emphysema secondary to AATD. These alterations could 
favor the hypothesis of lung carcinogenesis.
Some investigations have assessed the possible rela-
tion between AATD and the risk of lung cancer, with opposite 
results.15–18 All these studies have included a high percentage of 
smokers and exsmokers, and there is no study performed exclu-
sively in never-smokers. A study performed in never-smokers 
would eliminate the possible distortion caused by tobacco con-
sumption and therefore increase the validity of the study results. 
This advantage would be greater should the study retrieved infor-
mation on residential radon and environmental tobacco smoke.
The aim of this study is to analyze if it exists an associa-
tion between deficient AAT alleles, carried in homozygosis or 
heterozygosis and the risk of lung cancer in never-smokers. As 
a secondary objective, we aim to know if AATD could pose 
more risk in individuals exposed to environmental tobacco 
smoke for more than 20 years versus those exposed during a 
shorter period.
PATIENTS AND METHODS
We designed a multicentre hospital-based case–con-
trol study. Seven Galician hospitals and one in Asturias took 
part. Cases were all never-smoking lung cancer cases diag-
nosed at the participating hospitals between January 2011 and 
December 2013. Controls were never-smoking individuals 
who undergone nononcologic surgery, mainly major ambula-
tory surgery. To be classified as a never-smoker, we used the 
definition of the World Health Organization: to have smoked 
less than 100 cigarettes in lifetime or having smoked less than 
1 cig/day during 6 months. Controls were frequency-matched 
with cases on age and gender.
All participants were interviewed on their lifestyle, 
with special emphasis on environmental tobacco smoke 
exposure, previous occupations, leisure time activities, and 
diet and alcohol consumption. We measured residential radon 
in most participants’ homes after giving them a radon detec-
tor. The device was placed in the main bedroom at least dur-
ing 3 months. Environmental tobacco smoke exposure was 
defined as having lived with a smoker at least during the past 
20 years. Exposed individuals were asked about the relation-
ship with the smoker/s at the same dwelling, years of living, 
and number of daily cigarettes smoked by the cohabitant.
We searched for significant airflow obstruction in clini-
cal records of all patients with AATD (homozygous SS or 
ZZ, and heterozygous MS, MZ, or SZ) and also searched for 
emphysema using lung computed tomography images. This 
information allowed us to rule out COPD or emphysema in 
these AATD lung cancer patients.
Participants also donated 3 ml of total blood that was 
used to determine certain genetic polymorphisms, including 
deficient alleles for AAT S and Z, through analyzing the geno-
type. All samples were analyzed at the National Genotyping 
Center at the University of Santiago de Compostela. This 
facility has the most advanced techniques combined with rig-
orous quality control procedures.
Genotyping was performed using the MassARRAY 
iPLEX GOLD SNP genotyping system (Sequenom Inc., San 
Diego, CA), following the manufacturer’s instructions. The 
principles of this method are detailed in Buetow et al.19
The study protocol was approved by the Galician Ethics 
Committee (2010/295) and all participants signed a written 
consent to participate in this research.
Statistical Analysis
We first performed a univariate and bivariate analysis, 
describing the characteristics of cases and controls regarding 
age, gender, exposure to environmental tobacco smoke, and res-
idential radon. Afterwards, we performed a logistic regression 
where the dependent variable was the case or control status and 
the main independent variable being a carrier of S or Z alleles 
in homozygosis or heterozygosis. We did the same analysis for 
women (but not for men due to the low number on included 
males) and finally we analyzed if the risk of lung cancer for the 
deficient AAT alleles was different depending on having being 
exposed or not to environmental tobacco smoke during the past 
20 years. The results are expressed as ORs with 95% confidence 
intervals. The analysis was performed with SPSS version 20.
RESULTS
Two hundred and twelve cases and 318 controls were 
included. Table 1 shows the sample characteristics.
The median age of cases and controls was similar and 
also gender distribution, 81.8% of cases were women versus 
78.7% of controls. Residential radon exposure was available 
for 175 cases (82.5%) and 270 controls (84.9%). Of them, 
48% of cases were exposed to radon concentrations higher 
than 200 Bq/m3 compared with 30.4% of controls. The pre-
dominant histological type was adenocarcinoma (77.7%) fol-
lowed by squamous cell carcinoma (9.5%). We included 63 
AAT-deficient cases. All these cases except one had a lung CT 
scan. We did not find any case of lung emphysema and only 
in three cases localized bronchiectasis were described. Lung 
function tests were available in 26 of 63 AATD cases. In those 
cases with spirometry, it was normal in 19, it was obstruc-
tive in three cases and it showed a nonobstructive pattern in 
four cases. These three patients were, respectively, MS, MZ, 
and SS. 22.6% of cases had a heterozygous allele S compared 
with 29.9% of controls. Seven cases (3.3%) and three controls 
(0.9%) were homozygous SS. Heterozygous Z carriers were 
observed in 11 cases (5.2%) and 16 controls (5%). There were 
no ZZ homozygous individuals. The distribution of the dif-
ferent combinations of alleles and their risk of lung cancer is 
shown in Table 2.
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It can be observed that there is no apparent risk of 
lung cancer for heterozygous MS or MZ and neither for 
SZ patients. On the opposite, the adjusted risk for homozy-
gous SS individuals is 4.64 (95% confidence interval [CI]: 
1.08–19.92). When the analysis is restricted to women 
(Table 3), there is no significant effect for the different combi-
nations of heterozygous MS, MZ, or SZ. For heterozygous SS 
women the risk of lung cancer is 7.58 (95% CI: 1.40–40.87).
Table 4 displays the results for the combination of the 
different AAT genotypes combined with the exposure to envi-
ronmental tobacco smoke (measured as having lived with 
a smoker during the past 20 years). It can be observed that 
when the results are adjusted by age, gender, and residential 
radon exposure, homozygous SS individuals exposed to envi-
ronmental tobacco smoke present a lung cancer risk of 12.10 
(95% CI: 1.18–123.77), while those not exposed pose an OR 
of 1.75 (95% CI: 0.23–13.11), although there were only two 
SS homozygous cases in this last category. It was not possible 
to analyze the relation between SS genotype and the risk of 
lung cancer for the different histological types because all SS 
lung cancer cases were adenocarcinomas. This information 
might suggest specificity for AATD for this histological type.
DISCUSSION
The results of this study show for the first time for 
never-smokers that SS homozygous individuals pose a four-
fold lung cancer risk compared with those with the MM 
genotype. When the analysis is restricted to women the risk 
is seven times higher. We have also observed that the risk of 
lung cancer increases considerably for individuals with the SS 
genotype exposed to environmental tobacco smoke compared 
with those not exposed to environmental tobacco smoke. We 
have observed no effect for other AAT-deficient genotypes.
A very relevant aspect of our study is having included 
only never-smokers because we avoid possible biases caused 
by tobacco consumption on the results’ interpretation. 
Individuals who are AAT deficient are more susceptible to 
environmental aggressions and tobacco is the main deter-
minant of lung damage and it causes the appearance of lung 
emphysema and COPD.20,21
We reviewed lung CT scans and lung function tests in 
our AATD lung cancer cases. No cases of emphysema were 
described, and only in three cases localized, nonextensive, 
bronchiectasias were described. Not all lung cancer cases had 
a lung function test available in their medical chart, but among 
those cases whose lung function test could be reviewed we 
only found three with an obstructive pattern. In our opinion, 
these data show that there is no apparent association between 
emphysema or COPD with lung cancer in our sample of 
never-smokers. Furthermore, should an obstructive pattern be 
present, much more than half of our AATD patients would 
have a spirometry. This aspect supports the lack of association 
between AATD and an obstructive pattern in never-smoking 
lung cancer patients.
The SS genotype implies a moderate AATD. The 
increase in the risk of lung cancer caused by environmental 
tobacco smoke for those SS homozygous could be explained 
because tobacco particles could attract neutrophils to lung 
alveoli in response. Neutrophils release proteases in the alve-
oli and the most important is neutrophil elastase, which has 
to be neutralized by AAT. In patients with AATD this antipro-
tease capacity is diminished which might increase the risk of 
lung damage.22
AATD has two relevant characteristics. It is an infre-
quent genetic condition and this means that it is very difficult 
to perform studies with enough sample size to obtain results 
confirming or disregarding possible associations. It is also a 
very polymorphic gene and there exist ample variability with 
race and geography on the distribution of the different alleles. 
This fact makes difficult to generalize the results obtained by 
different studies.
Numerous studies have been published on the frequen-
cies of normal (M) and deficient alleles (S and Z) and some 
of them in Spanish population. A study performed in Asturias, 
TABLE 1.  Sample Description
Variable
Cases, n (%) Controls, n (%)
n = 212 n = 318
Age
  Median 70 70
  P25–P75 61–77 63.5–79
  Range 34–87 43–90
Gender
  Female 172 (81.1) 250 (78.7)
  Male 40 (18.9) 68 (21.3)
Education
  No formal studies 54 (26.1) 51 (16.0)
  Primary school 124 (59.9) 236 (74.2)
  High school 15 (7.2) 19 (6.0)
  University degree 14 (6.8) 12 (3.8)
Residential radon exposure (Bq/m3)
  <200 91 (52) 188 (69.6)
  >200 84 (48) 82 (30.4)
Exposure to ETS at home in past 20 years
  Yes 95 (44.8) 144 (45.4)
  No 117 (55.2) 173 (54.6)
Histological types
  Adenocarcinoma 164 (77.7)
  Squamous cell carcinoma 20 (9.5)
  Small-cell carcinoma 12 (5.7)
  Large-cell carcinoma 7 (3.3)
  Other histological types 8 (3.8)
AAT mutations
  S
   Not present 157 (74.1) 220 (69.2)
   Heterozygosis 48 (22.6) 95 (29.9)
   Homozygosis 7 (3.3) 3 (0.9)
  Z
   Not present 201 (94.8) 302 (95)
   Heterozygosis 11 (5.2) 16 (5)
   Homozygosis 0 0
ETS, environmental tobacco smoke; AAT, alpha-1 antitrypsin.
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Spain,23 observed frequencies of PiS and PiZ of 100 and 20 
per 1000 inhabitants, respectively. Other study performed in 
Barcelona24 including 440 participants observed frequencies 
of 104 and 16 per 1000. The first study performed in Spanish 
population was performed in Oslo in 1968 and it included 378 
sailors, most of them from Galicia.25 It found frequencies of 
PiS and PiZ of 112 and 12 per 1000. Our study shows that the 
frequencies of the deficient alleles S and Z are higher than 
those described previously in Spain. We have not detected 
homozygous ZZ and the distribution of the other genotypes 
is similar between cases and controls with the exception of 
homozygous SS, whose frequency is higher in cases than 
control (3.3% vs. 0.9%). It is known that there is a gradi-
ent Northwest-Southeast in Spain regarding deficient AAT 
individuals and this fact could justify the higher prevalence 
of deficient alleles that we have observed in Galicia.26 In a 
previous review published in 1998 on the frequencies of defi-
cient alleles, the highest rates of S mutations were observed 
in Galicia and Portugal. The authors suggested that probably 
S mutation was originated in this geographical area in an 
unknown date.27 We should also highlight that the available 
studies have not used the genotyping technology of our study 
and allele frequencies have been estimated previously using 
the phenotype,23,24,28 which is a less reliable method.
Environmental tobacco smoke has been classified as a 
human carcinogen29,30 and this study suggests a possible inter-
action between this exposure and AATD, but only for homo-
zygous SS. Five of seven SS individuals have been exposed to 
environmental tobacco smoke for more than 20 years and lung 
cancer risk for them is 12.10 (1.18–123.77) while in those not 
exposed (n = 2) the risk is not statistically significant 1.75 
(0.23–13.11).
There are various carcinogenic mechanisms that have 
been proposed for lung cancer development in AATD individ-
uals. These are mainly derived from the excess of neutrophil 
elastase, which could facilitate tissue damage and air trapping 
TABLE 2.  AAT Genotype and Risk of Lung Cancer
Cases, n (%) Controls, n (%) OR (95%CI)a p OR (95%CI)b p
AAT
  MM 149 (70) 208 (65.4) 1 (-) 1 (-)
  MS 45 (21.1) 91 (28.6) 0.66 (0.41–1.05) 0.08 0.67 (0.42–1.08) 0.10
  MZ 8 (3.8) 12 (3.8) 0.75 (0.27–21.09) 0.58 0.85 (0.30–2.40) 0.76
  SZ 3 (1.4) 4 (1.3) 1.25 (0.27–5.78) 0.78 0.94 (0.20–4.48) 0.94
  SS 7 (3.3) 3 (0.9) 3.38 (0.81–13.99) 0.09 4.64 (1.08–19.92) 0.04
ETS exposure
  No 117 (55.2) 173 (54.6) - - 1 (-)
  Yes 95 (44.8) 144 (45.4) - - 0.78 (0.52–1.18) 0.25
Radon exposure
  <200 Bq/m3 91 (52) 188 (69.6) - – 1 (-)
  ≥200 Bq/m3 84 (48) 82 (30.4) - - 2.36 (1.60–3.58) <0.01
aOR adjusted by age and gender.
bOR adjusted by age, gender, ETS, and residential radon exposure (<200, >200 Bq/m3).
AAT, alpha-1 antitrypsin; OR, odds ratio; CI, confidence interval; ETS, environmental tobacco smoke.
TABLE 3.  AAT Genotype and Lung Cancer Risk in Never-Smoking Women
Cases, n (%) Controls, n (%) OR (95% CI)a p OR (95% CI)b p
AAT
  MM 120 (69.8) 162 (64.8) 1 (-) 1 (-)
  MS 34 (19.8) 73 (29.2) 0.68 (0.40–1.16) 0.16 0.70 (0.41–1.21) 0.21
  MZ 8 (4.6) 11 (4.4) 0.86 (0.30–2.44) 0.77 1.06 (0.36–3.07) 0.92
  SZ 3 (1.7) 2 (0.8) 2.44 (0.39–15.15) 0.34 2.02 (0.31–13.01) 0.46
  SS 7 (4.1) 2 (0.8) 5.02 (0.97–25.83) 0.05 7.58 (1.40–40.87) 0.02
ETS exposure
  No 85 (49.4) 121 (48.6) (-) 1 (-)
  Yes 87 (50.6) 128 (51.4) (-) 0.77 (0.49–1.21) 0.25
Radon exposure
  <200 Bq/m3 85 (54.5) 155 (73.1) (-) 1 (-)
  ≥200 Bq/m3 71 (45.5) 57 (26.9) (-) 2.80 (1.74–4.51) <0.01
aOR adjusted by age.
bOR adjusted by age, ETS, and residential radon exposure (<200, >200 Bq/m3).
AAT, alpha-1 antitrypsin; OR, odds ratio; CI, confidence interval; ETS, environmental tobacco smoke.
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favoring a longer exposure to carcinogens in the alveoli. It can 
also promote tumor progression through the tumor necrosis 
factor receptor signaling pathway,31 by inhibition of apoptosis. 
Neutrophil elastase can activate matrix metalloproteinases, a 
group of enzymes that have a role in tumor invasion and metas-
tasis.32 Some studies have suggested that high levels of neutro-
phil elastase, main substrate of AAT, could have a role in lung 
carcinogenesis, not only in AATD but even in individuals with 
normal AAT concentration. Seric levels of neutrophil elastase 
are defined by ELA2 gen that have two known polymorphisms 
and they encode and produce a different amount of protein.33,34
Other studies have observed that lung cancer risk 
increases in AATD individuals, but all of them included a high 
proportion of smokers and ex-smokers. Yang et al. observed a 
13.4% of carriers of a deficient allele among cases and 7.8% 
among controls. In this study, being a carrier of one or two 
deficient alleles was associated with a lung cancer risk of 
1.7 (95% CI: 1.2–2.4).18 Other study performed in Serbian 
population16 found a prevalence of deficient heterozygous 
alleles of 5.9% in cases and 3.7% in controls. Being a het-
erozygous-deficient carrier Z or S was associated with lung 
cancer risk (squamous cell histological type) of 4.51 (95% CI: 
1.66–12.29), whereas no risk excess was observed for other 
histological types. We were not able to analyze other histologi-
cal types because all homozygous SS were adenocarcinomas. 
This histological type comprised 77.7% of all cancer cases in 
our study.
All previously published studies have included a wide 
majority of ever-smokers and a very low number of never-
smokers that have not been analyzed separately. It is known 
that protease–antiprotease imbalance can increase lung tissue 
damage in response to exposure to tobacco smoke but in never 
smoking people the relevance of this pathway is unclear. In 
fact, there is a high proportion of never-smokers with severe 
AAT deficiency (PiZZ) that does not develop pulmonary 
emphysema in their lifetime. This information suggests that 
more studies are necessary to explore the possibility of an 
alternative pathway for lung carcinogenesis in never-smoking 
AAT-deficient individuals.
This study has some limitations. The main one is the 
low number of deficient individuals (heterozygous and homo-
zygous), but this limitation is common to all available studies. 
Other limitation is that we have not measured serum levels 
of AAT nor its main substrate, neutrophil elastase. Some 
authors have hypothesized that imbalance between AAT and 
neutrophil elastase may be critical in the causal pathway from 
tobacco smoke exposure to lung cancer development (33) 
but its specific role in the carcinogenesis in never-smokers is 
unknown. Very few studies have measured neutrophil elastase 
and this practice should be recommended in investigations 
evaluating AATD.
Regarding seric levels of AAT, it is well defined in the 
literature that S allele implies a moderate AAT deficiency 
with a consequent reduction of antielastase activity. We did 
not measured AAT levels due to logistic reasons. Many stud-
ies assessing AAT role have not also measured AAT dosage 
in serum and it is important to have its levels to have a better 
picture of the effect of AATD. We could take as a reference for TA
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participants in our study the results of a previous study from 
Vidal et al done in Spanish population (24) where plasmatic 
levels of AAT associated with each genotype were: MM: 
103–200 mg/dl, MS: 100–180 mg/dl, SS: 70–105 mg/dl, MZ: 
66–120 mg/dl, SZ: 45–80 mg/dl, ZZ: 10–40 mg/dl. A last limi-
tation is that we have not analyzed polymorphisms of other 
genes that might play a role in lung cancer onset.
Our study has also important advantages. It has included 
only never-smokers, a relatively high number of cases and 
controls, we have measured environmental tobacco smoke 
exposure and also residential radon exposure. There are no 
published studies on AATD with these characteristics. The 
most important advantage is that we have been able to include 
a relatively high sample size comprised of never-smokers, 
allowing assessing the effect of AAT-deficient alleles S and Z 
without confounding by tobacco consumption.
To conclude, the results of this study suggest that being 
a homozygous SS increases importantly the risk of lung can-
cer in never-smokers. This risk is higher for women and for 
individuals exposed to environmental tobacco smoke, sug-
gesting a possible interaction. AATD is an under diagnosed 
condition and a potential deficiency should be considered for 
never-smoking lung cancer cases with adenocarcinoma.
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